ToeFX Light Therapy for Chronic Venous Leg Ulcers
Adjunctive ToeFX Photodynamic Therapy for Chronic Venous Leg Ulcers: A Single-Arm, Open-Label Pilot Feasibility Study
Chronic venous leg ulcers can be painful and prone to infection. They can significantly limit a patient's function, mobility and quality of life.
A major contributor to delayed ulcer healing is persistent bacteria. Treatments that can penetrate the bacteria's protective outer shield to kill and clear the bacteria are important for helping ulcers heal more quickly.
The purpose of this pilot study is to test a topical study treatment (called ClearToe Serum®) plus two types of light (red and blue-purple light) in the treatment of chronic venous ulcers.
This is an open-label single-arm pilot study. All participants will receive the test treatment as well as standard or care treatment for their chronic venous ulcer. Participants will receive study treatments one per week for up to 12 weeks, or until their ulcer is healed.
The main objectives are to assess adherence to the one-per-week study treatments, and to note any study device-related, study treatment-related, or serious adverse events, or adverse events that lead to stopping study treatment.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Chronic venous leg ulcers (VLUs) are a common and costly. They affect about 1% adults and are a significant burden to patients and the healthcare system. VLUs are often painful, malodorous, and prone to infection. They can have a big impact a patient's function, mobility, and quality of life. Standard of care (SOC) treatment, meaning the usual treatment, includes compression therapy, regular wound care (removing dead tissue, cleaning and dressing the wound), and infection management. Even with SOC treatment, about half of VLUs persist for months or years.
A major contributor to delayed healing is persistent bacterial infection, including bacteria that produce a biofilm, a protective covering resistant to many topical and systemic antibiotics. Strategies that can penetrate the biofilm to reduce local bacterial infection without contributing to antibiotic resistance are of particular interest in chronic wound management.
ToeFX has developed a non-thermal photodynamic therapy (PDT) platform that combines a methylene-blue-based photosensitizer (ClearToe® serum) with 660 nm light irradiation. Upon activation by light of the appropriate wavelength, the photosensitizer generates reactive oxygen species that are toxic to a broad range of bacteria but harmless for host tissue. This mechanism of photodynamic disinfection is well established in other clinical contexts, and the ToeFX platform is currently approved/registered for other indications. The ToeFX ClearToe® system is approved by Health Canada for the treatment of onychomycosis (toenail fungus). Its potential to reduce local bioburden and support a more favourable wound-healing environment has not yet been formally evaluated in venous leg ulcers.
This pilot study is intended to evaluate the feasibility (treatment adherence) and safety of ToeFX photodynamic therapy as an adjunct to SOC in a defined population of patients with chronic venous leg ulcers, while collecting preliminary clinical, wound-healing, and patient-reported outcome data to inform the design of a future, larger controlled trial.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Ahmed Kayssi, MD MSc FRCSC
- 電話番号:(416) 691-2030
- メール:ahmed.kayssi@sunnybrook.ca
研究場所
-
-
Ontario
-
Toronto、Ontario、カナダ、M4L 3Y3
- East Toronto Vascular Clinic
-
コンタクト:
- Ahmed Kayssi, MD MSc FRCSC
- 電話番号:(416) 691-2030
- メール:ahmed.kayssi@sunnybrook.ca
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18 years or older
- Able to attend weekly visits for up to 12 weeks
- Chronic venous leg ulcer (CEAP C6) of the lower extremity
- Ulcer duration of 4 weeks or more
- Ulcer size between 1 cm² and 20 cm² at baseline
- Receiving standard-of-care compression therapy, or eligible to initiate it
- Able to provide informed consent and comply with study procedures
Exclusion Criteria:
- Wound location or anatomy not compatible with the ToeFX photodynamic therapy device
- Systemic infection (e.g., fever, sepsis, spreading cellulitis) or wound requiring systemic antibiotics
- Necrotic tissue over 25% of the wound bed, exposed bone or tendon, deep abscess, osteomyelitis or gangrene
- Severe ischemia (ABI below 0.5) or poorly controlled diabetes (HbA1c above 10%)
- Heavy exudate requiring negative-pressure wound therapy
- Known photosensitivity or allergy to methylene blue or light-based therapies
- Immunosuppressive therapy, radiation or chemotherapy within the past 3 months, or active malignancy
- Pregnancy or lactation
- Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
- Participation in another interventional study within 30 days of screening
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:デバイスの実現可能性
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:ToeFX Treatment
Weekly ToeFX treatment of venous leg ulcer up to 12 weeks or wound closure |
Non-thermal photodynamic therapy platform that combines a methylene-blue-based photosensitizer ( ClearToe® serum) with 660 nm light irradiation
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Treatment adherence
時間枠:Baseline through Visit 12/ end of treatment (up to 12 weeks)
|
Percentage of planned ToeFX treatment sessions completed per participant, and reasons for missed or discontinued sessions |
Baseline through Visit 12/ end of treatment (up to 12 weeks)
|
|
Safety: Adverse Events
時間枠:Baseline through Healing Confirmation Visit (up to 14 weeks)
|
Incidence and severity of adverse events (AEs), serious adverse events (SAEs), device-related AEs, treatment-related AEs, and study discontinuations due to AEs |
Baseline through Healing Confirmation Visit (up to 14 weeks)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percent Change in Wound Area From Baseline
時間枠:Baseline, week 4, week 8, and week 12
|
Percent change in wound area (cm²) from baseline |
Baseline, week 4, week 8, and week 12
|
|
Complete wound epithelialization
時間枠:12 weeks
|
Proportion of participants achieving complete epithelialization by Week 12, as assessed by clinician |
12 weeks
|
|
Time to complete wound healing
時間枠:12 weeks
|
Time (days) from baseline to complete epithelialization |
12 weeks
|
|
Change in Bates-Jensen Wound Assessment Tool (BWAT) score
時間枠:Baseline to 12 weeks/ end of treatment
|
Change in wound bed characteristics measured using the BWAT |
Baseline to 12 weeks/ end of treatment
|
|
Change in pain score
時間枠:Baseline to 12 weeks/ end of treatment
|
Change in pain score (0-10 Numeric Rating Scale) |
Baseline to 12 weeks/ end of treatment
|
|
Change in health-related quality of life
時間枠:12 weeks/ end of treatment
|
Change in EQ-5D-5L score |
12 weeks/ end of treatment
|
|
Patient satisfaction
時間枠:12 weeks/ end of treatment
|
Patient-reported satisfaction with treatment measured by study-specific patient satisfaction questionnaire |
12 weeks/ end of treatment
|
|
Clinician feasibility
時間枠:14 weeks or earlier if wound healing
|
Qualitative and operational observations on feasibility of integrating PDF into routine wound care workflow |
14 weeks or earlier if wound healing
|
|
Absolute Change in Wound Area From Baseline
時間枠:Baseline, week 4, week 8, and week 12
|
Absolute change in wound area (cm²) from baseline |
Baseline, week 4, week 8, and week 12
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Ahmed Kayssi, MD MSc FRCSC、East Toronto Vascular Clinic
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- PRO04244160_ToeFX
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
This is a small single-centre pilot study. Individual participant data will not be shared because of participant privacy considerations and the terms of the clinical trial agreement with the study funder. Data are de-identified using study IDs and stored with restricted access. Aggregate results will be published.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。